Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support... see more

PINL:GRPOF - Post Discussion

View:
Post by Kingofstockst on Dec 10, 2020 12:51pm

Science

And facts don't lie, are they a perfectly run company? Maybe not but none really are, even in life somethings get pushed aside here and there but the focus has been the same, yes ards03 came to the forefront but so did this pandemic. I know for a fact the same ppl complaining here would have destroyed Guy for not pursuing ards03 after learning that they had all that data. If you don't believe anymore sell and move on, otherwise buy and hold GLTA
Comment by FormerSupporter on Dec 10, 2020 1:39pm
Thanks for your comment. I believe that ARDS is not the problem. It make a nice addition to the pipeline. The problem is the lack of focus and funds to make ARDS or any of thier early stage assets a success. They keep on jumping from prospect to prospect righ before they take it into the clinic.  As mentioned I believe that ARDS, QIXLEEF and CAUMZS all have good potential but they are in the ...more  
Comment by Kingofstockst on Dec 10, 2020 1:50pm
But speaking on ards03 you would know from NR's that the partnership with George Mason University is awesome as there covering 90% of funding. Did you miss that?
Comment by FormerSupporter on Dec 10, 2020 2:03pm
I did read and just reread the October 22 news release in which Tetra discuss ARDS and George Mason University. I agree that George Mason is very prestigous to Tetra and that they should be able to add value. That news release does not mention anything about George Mason covering any of the funding let alone 90%. In these partnerships with universities it usually works the other way around as ...more  
Comment by Kingofstockst on Dec 10, 2020 2:31pm
It's actually 1 of the townhall videos with Guy, and out of his own mouth 90%, you can try and find it otherwise ill try and look for it once I get home tonight.
Comment by FormerSupporter on Dec 10, 2020 5:00pm
Thank you. I found the link on the website and will give it a listen tonight.
Comment by FormerSupporter on Dec 11, 2020 9:33am
I listened to the town hall as well as the questions after the presentation afterwards and that is were Guy mentioned 90% of the research program. With Guy failing to answer the question of dollar amount and scope of the program, I believe he was misleading in just what is being paid by George Mason. I think it is a small cost program either required or desired by Guy at a pre clinical level. I ...more  
Comment by Realnewsalways1 on Dec 11, 2020 10:30am
The main point with GMU is the association with them. They would not partner with Tetra unless the research did not support their  thesis. The cost savings, whatever they may be will be appreciated, but also GMU will bring other eyes in the Pharma business to Tetra. The FACTS are, new research on the dime of GMU, new patnership opportunities by being associated with GMU, Access to the US ...more  
Comment by Kingofstockst on Dec 11, 2020 11:30am
Very well said lots of benefits with gmu nothing to lose, if you don't see that and pick the negatives out that's on you then...
Comment by FormerSupporter on Dec 11, 2020 1:02pm
I agree with the GMU discussion and the potential benefit to Tetra. The negative that cannot be ignored stems from the failure of Tetra to provide clear and accurate communication and updates to its shareholders and not keep everything clocked in so much mystery and secrets that the entire market discounts what is being issued by Tetra. If Guy can simply tell us what has been achieved and what ...more  
Comment by Realnewsalways1 on Dec 11, 2020 2:47pm
In hindsight yes they should have reaised 50mil when were at $0.53. We would still be at .50 if that were the case. Also, to correct your numbers, I believe it is  $1m/month when we are in trials which now are in. Best of luck and fortune to everyone
Comment by Kingofstockst on Dec 10, 2020 2:52pm
I think it was the Oct 27 townhall at around 20:54 of the video...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities